Social network
Our Company - Contributing with pride and passion, beyond expectations
Our Company - Contributing with pride and passion, beyond expectations

Our Company

Contributing with pride and passion, beyond expectations

Tools content (print, share, increase/decrease text size):


Middle area:

Sanofi reaffirms its commitment to diabetes at the EASD 2012 Congress


October 1, 2012


There were approximately 366 million people worldwide with diabetes in 2011 (1). The outlook for the future is not very optimistic as more than 552 million people will have diabetes by 2030 (1). It is estimated that more than 50% of patients in the United States and Europe (2) are unable to regulate their blood sugar. The 48th Congress of the EASD (European Association for the Study of Diabetes) offers an opportunity for Sanofi to reaffirm its commitment to the comprehensive care of patients with diabetes and the personalized management of diabetes.


Sanofi at EASD 2012

The 48th EASD Congress to be held in Berlin from October 1 to 5, 2012 is an important event for the international scientific community. Sanofi will be using this opportunity to comment on the latest clinical results of its research (28 publications have been accepted) during a Press Conference, to sponsor a symposium on the management of diabetes* and to continue its dialogue with international experts. Sanofi has chosen not only to produce and supply insulin, but also to offer people with diabetes a “World of Solutions” that meets their needs and enables them to manage their condition on an everyday basis. The solutions include injectable and oral treatments**, innovative and easy to use medical devices*** that are adapted to their lifestyle, and personalized services. On October 2, this distinctly patient-centric approach will be discussed by a panel of experts around the theme of “How Could the new ADA/EASD position statement on type 2 diabetes improve diabetes care?” Sanofi will also meet with several dozen specialists in a Networking Forum with the aim of showcasing its portfolio and future treatments, and above all encouraging them to develop professional networks to combine their efforts to control the disease.

All these activities, together with the presence at EASD of CEO Christopher A. Viehbacher, underline the importance of Sanofi’s contributions to the fight against diabetes and its commitment to improving the quality of life for patients and to support health professionals.

Download the “Start right - Eat right: Quick-tips for healthy living” brochure (PDF)

To find out more:


Diabetes: a public health priority

Every country in the world is affected by the growing diabetes epidemic including emerging countries, where about two thirds of diabetics go undiagnosed (3). For Sanofi, this public health challenge can only be met by combining comprehensive patient care solutions with partnerships that drive educational and support projects for communities as “Siempre a tu lado” in Mexico and training for health professionals such as “E-diabetes” in Africa. Sanofi also works closely with local organizations in China, for example, on the “Going Beyond Together - Caring for Type 1” project.


Sanofi's commitment to fighting diabetes in China

China is particularly affected by the epidemic, with 92 million patients diagnosed (4) - the highest rate in the world - and a large population of Type 1 patients who are largely under-diagnosed and overlooked. This is why Sanofi is engaging strongly with Chinese authorities and the scientific community to implement projects with an educational and training focus. This commitment also involves research into new treatments and the production of insulin and medical devices to provide Chinese patients with global care solutions.


“Going Beyond Together - Caring for Type 1”

The “Going Beyond Together - Caring for Type 1” project led by Sanofi in collaboration with the Chinese Diabetes Society (CDS) is based on the results of the 3C (Coverage, Cost, Care) study that highlights the unmet needs of Chinese with type 1 diabetes. The project aims to raise awareness of the disease, eliminate discrimination, and optimize treatment standards and care. The results of the 3C study launched in 2011 also provide a better understanding of healthcare coverage and costs. The Chinese Diabetes Society has called for higher levels of reimbursement for outpatient treatment in an effort to reduce the financial burden for patients with type 1 diabetes and their families.


Training programs for healthcare professionals

Sanofi is collaborating with the Chinese government and the scientific community to improve diabetes management by training physicians and educating patients. For example, Sanofi is supporting the “China Initiative for Diabetes Excellence (CIDE)” that plans to train 500 diabetes emerging experts and 8,000 rural community doctors. This five-year initiative is led by the Chinese Center for Disease Control and Prevention at the Ministry of Health, the Chinese Diabetes Society and the WHO Collaboration Center at the International Diabetes Center.


From research to production

In the field of clinical research, Sanofi is supporting such major programs as the China Type 2 Diabetes Research Project involving 46,000 diabetic and non-diabetic individuals and an extensive observational study on treating diabetes with basal insulin (Observational Registry for Basal Insulin Treatment - ORBIT Study).

In May 2012, Sanofi inaugurated a new assembling and packaging line to produce its flagship Lantus® SoloSTAR® pre-filled insulin injection pen at its Beijing plant located in the Beijing Economic-Technological Development Area (BDA). The second phase of this US$90 million project will be to install a high-tech aseptic insulin cartridge production line. With a designed capacity of 48 million units per year, the facility is expected to help fulfill the needs of people with diabetes and ultimately improve the standards of diabetes care in China.




(1) International Diabetes Federation, Diabetes Atlas, 5th edition
(2) Adelphi Disease Specific Program (DSP) II and VII (sample of over 10.000 diabetic patient records)
(3) Internal estimates based on multiple sources
(4) New England Journal of Medicine. 2010;362:1090-101


© Sanofi 2004-2016 - All rights reserved - Update: March 10, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)